Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade

Journal of Urology

Volumn 157, Issue 5, 1997, Pages 1731-1735

  Schellhammer, Paul F ^a   Venner, Peter ^a   Haas, Gabriel P ^a   Small, Eric J ^a   Nieh, Peter T ^a   Seabaugh, D Rusby ^a   Patterson, A Lynn ^a   Klein, Eric ^a   Wajsman, Zev ^a   Furr, Barry ^a   Chen, Yusong ^a   Kolvenbag, Geert J C M ^a  

^a NONE

Author keywords

androgens; flutamide; prostate specific antigen; prostatic neoplasms

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0031001274     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64846-8     Document Type: Article

References (20)

1. Kelly, W. K. and Scher, H. I.: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol., 149: 607, 1993.
2. Scher, H. I. and Kelly, W. K.: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566, 1993.
3. Figg, W. D., Sartor, O., Cooper, M. R., Thibault, A., Bergan, R. C., Dawson, N., Reed, E. and Myers, C. E.: Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Amer. J. Med., 98:412, 1995.
4. Herrada, J., Dieringer, P. and Logothetis, C. J.: Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J. Urol., 155: 620, 1996.
5. Dupont, A., Gomez, J.-L., Cusan, L., Koutsilieris, M. and Labrie, F.: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150: 908, 1993.
6. Sartor, O., Cooper, M., Weinberger, M., Headlee, D., Tompkins, A., Thibault, A. and Myers, C. E.: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone refractory" prostate cancer. J. Nat. Cancer Inst., 86: 222, 1994.
7. Small, E. J. and Srinivas, S.: The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer, 76: 1428, 1995.
8. Small, E. J. and Carroll, P. R.: Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology, 43: 408, 1994.
9. Nieh, P. T.: Withdrawal phenomenon with the antiandrogen casodex. J. Urol., part 2, 153: 1070, 1995.
10. Schellhammer, P., Sharifi, R., Block, N., Soloway, M., Venner, P., Patterson, A. L., Sarosdy, M., Vogelzang, N., Jones, J. and Kolvenbag, G. for the Casodex Combination Study Group: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology, 45: 745, 1995.
11. Schellhammer, P., Sharifi, R., Block, N., Soloway, M., Venner, P., Patterson, A. L., Sarosdy, M., Vogelzang, N., Jones, J. and Kolvenbag, G. for the Casodex Combination Study Group: Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology, suppl. IA, 47: 54, 1996.
12. Kolvenbag, G. J. and Blackledge, G. R.: Worldwide activity and safety of bicalutamide: a summary review. Urology, suppl. IA, 47: 70, 1996.
13. Culig, Z., Klocker, H., Eberle, J., Kaspar, F., Hobisch, A., Cronauer, M. V. and Bartsch, G.: DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate, 22: 11, 1993.
14. Wilding, G., Chen, M. and Gelmann, E. P.: Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate, 14: 103, 1989.
15. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A. and Mulder, E.: Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry, 31: 2393, 1992.
16. Veldscholte, J., Berrevoets, C. A., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Trapman, J., Brinkmann, A. O. and Mulder, E.: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol., 41: 665, 1992.
17. Kemppainen, J. A. and Wilson, E. M.: Agonist and antagonist activities of hydroxyflutamide and casodex relate to androgen receptor stabilization. Urology, 48: 157, 1996.
18. ® for prostate cancer: PSA declines in patients with flutamide withdrawal responses. Proc. Amer. Soc. Clin. Oncol., 232: abstract 603, 1995.
19. Scher, H. I., Zhang, Z. F., Nanus, D. and Kelly, W. K.: Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology, suppl. 1A, 47: 61, 1996.
20. Kelly, W. K., Curley, T., Liebertz, C., Kim, B. and Scher, H. I.: Phase II trial of 13-cis retinoic acid and interferon-alpha 2a in patients with adenocarcinoma of the prostate. Proc. Amer. Soc. Clin. Oncol., 254: abstract 652, 1996.